VCYT vs. GTH, BNR, PSNL, RDNT, GH, FTRE, CDNA, VRDN, CSTL, and FLGT
Should you be buying Veracyte stock or one of its competitors? The main competitors of Veracyte include Genetron (GTH), Burning Rock Biotech (BNR), Personalis (PSNL), RadNet (RDNT), Guardant Health (GH), Fortrea (FTRE), CareDx (CDNA), Viridian Therapeutics (VRDN), Castle Biosciences (CSTL), and Fulgent Genetics (FLGT).
Veracyte (NASDAQ:VCYT) and Genetron (NASDAQ:GTH) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, community ranking, institutional ownership and profitability.
10.7% of Genetron shares are held by institutional investors. 1.3% of Veracyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Veracyte received 429 more outperform votes than Genetron when rated by MarketBeat users. Likewise, 72.93% of users gave Veracyte an outperform vote while only 33.33% of users gave Genetron an outperform vote.
Veracyte has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, Genetron has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.
In the previous week, Veracyte had 6 more articles in the media than Genetron. MarketBeat recorded 6 mentions for Veracyte and 0 mentions for Genetron. Veracyte's average media sentiment score of 0.82 beat Genetron's score of 0.00 indicating that Veracyte is being referred to more favorably in the media.
Veracyte presently has a consensus price target of $27.50, indicating a potential upside of 32.53%. Given Veracyte's higher probable upside, research analysts clearly believe Veracyte is more favorable than Genetron.
Genetron has a net margin of 0.00% compared to Veracyte's net margin of -18.16%. Genetron's return on equity of 0.00% beat Veracyte's return on equity.
Veracyte has higher revenue and earnings than Genetron.
Summary
Veracyte beats Genetron on 11 of the 15 factors compared between the two stocks.
Get Veracyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Veracyte Competitors List
Related Companies and Tools
